Alert detail
Medical Devices; Neurological Devices; Classification of the Transcutaneous Electrical Nerve Stimulator To Treat Fibromyalgia Symptoms
Policy ID: 2026-10675Specialty: Multi-specialtyAdded: 6/2/2026Effective: 2026-05-29federal rule
What changed
Final Rule published 2026-05-29. The Food and Drug Administration (FDA) is classifying the transcutaneous electrical nerve stimulator to treat fibromyalgia symptoms into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the transcutaneous electrical nerve stimulator to treat fibromyalgia symptoms. We are taki
Who’s affected: Multi-specialty billing teams · Effective: 2026-05-29
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.
Not ready to subscribe?
Get the free weekly reimbursement brief for Multi-specialty— the week’s changes and deadlines, delivered to your inbox. No account required.